Melanoma Clinical Trials

Showing 61-80 of 1,145 trials

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

NCT06287463

This is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

Advanced Solid TumorRAF MutationRAS Mutation+7 more

Deciphera Pharmaceuticals, LLC29 participantsStarted May 2024

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +6 more locations

COMPLETEDPhase 1

IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma

NCT04335890

A Phase I vaccination trial in patients suffering from recently diagnosed metastatic uveal melanoma not cureable with local therapy and needing systemic therapy. IKKb-matured Dendritic Cells loaded with autologous tumor-RNA + RNA coding for defined antigens and driver mutations will be added to a standard therapy chosen by the tumor board (either checkpoint blockade or chemotherapy).

Melanoma, Uveal Metastatic

Hasumi International Research Foundation17 participantsStarted Sep 2020

Erlangen, Bavaria, Germany

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma

Related Searches

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma

RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

A Phase II Trial of LM103 in Advanced Melanoma

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Video Education With Result Dependent dIsclosure

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Circulating Tumor DNA in Melanoma Patients

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health Centers